The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Spatial remodeling of the tumor-immune microenvironment (TIME) on neoadjuvant chemo-immunotherapy (NCIT) in patients (pts) with hormone receptor positive (HR+) early breast cancer (eBC) by multiplex immunofluorescence (mIF).
 
Chiara Corti
Honoraria - Pulse Health Sciences
Research Funding - Lilly (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Beyza Koca
No Relationships to Disclose
 
Tianyu Li
No Relationships to Disclose
 
Yasemin Sahinbas
No Relationships to Disclose
 
Busem Binboga Kurt
No Relationships to Disclose
 
Hajer Rahee
No Relationships to Disclose
 
Lauren O'Keeffe
No Relationships to Disclose
 
Fangyuan Chen
No Relationships to Disclose
 
Adrienne Parsons
No Relationships to Disclose
 
Tasnim Rahman
No Relationships to Disclose
 
Maxime Meylan
No Relationships to Disclose
 
Xiangying Chu
No Relationships to Disclose
 
Jon Ladd
Employment - RareCyte
 
Edward Lo
Employment - RareCyte
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Nabihah Tayob
No Relationships to Disclose
 
Sara Tolaney
Consulting or Advisory Role - AADi; Aktis Oncology; Ambrx; Arvinas; AstraZeneca; Avenzo Therapeutics; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Boehringer Ingelheim; Boundless Bio; Bristol-Myers Squibb; Celcuity; Circle Pharma; Corcept Therapeutics; Cullinan Oncology; Daiichi Sankyo; Denali Therapeutics; eFFECTOR Therapeutics; Eisai; Ellipses Pharma; Genentech; Immunomedics/Gilead; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Novartis; Olema Pharmaceuticals; Pfizer; Reveal Genomics; Samsung Bioepis; Seagen; Summit Therapeutics; Systimmune; Tempus; Zuellig Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; AstraZeneca; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Adrienne Waks
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - Ambrx; AstraZeneca; Jazz Pharmaceuticals; Johnson and Johnson; Pfizer
Research Funding - Genentech (Inst); Gilead Sciences (Inst); Macrogenics; Merck (Inst); Tersera
 
Elizabeth Mittendorf
Consulting or Advisory Role - Alight Sciences; AstraZeneca; Merck
Research Funding - Gilead Sciences (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Roche/Genentech